
    
      This is an international, multicenter, open-label, 2-arm follow-on study of the safety,
      tolerability, and efficacy of AR101 in peanut-allergic individuals who have completed the
      ARC003 study. This study will explore alternative dosing regimens during extended maintenance
      with AR101.
    
  